343 related articles for article (PubMed ID: 27762512)
1. Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial.
Goyal O; Sidhu SS; Sehgal N; Puri S
J Assoc Physicians India; 2016 Sep; 64(9):30-35. PubMed ID: 27762512
[TBL] [Abstract][Full Text] [Related]
2. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
Sharma P; Kumar A; Shrama BC; Sarin SK
Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
[TBL] [Abstract][Full Text] [Related]
3. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
Ghosh S; Choudhary NS; Sharma AK; Singh B; Kumar P; Agarwal R; Sharma N; Bhalla A; Chawla YK; Singh V
Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
[TBL] [Abstract][Full Text] [Related]
4. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
[TBL] [Abstract][Full Text] [Related]
5. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study.
Singh V; Ghosh S; Singh B; Kumar P; Sharma N; Bhalla A; Sharma AK; Choudhary NS; Chawla Y; Nain CK
J Hepatol; 2012 Jun; 56(6):1293-8. PubMed ID: 22322237
[TBL] [Abstract][Full Text] [Related]
6. Terlipressin therapy for renal failure in cirrhosis.
Triantos CK; Samonakis D; Thalheimer U; Cholongitas E; Senzolo M; Marelli L; Leandro G; Patch D; Burroughs AK
Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):481-6. PubMed ID: 19952764
[TBL] [Abstract][Full Text] [Related]
7. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.
Muñoz LE; Alcalá EG; Cordero P; Martínez MA; Vázquez NY; Galindo S; Mendoza E; Segura JJ
Ann Hepatol; 2009; 8(3):207-11. PubMed ID: 19841499
[TBL] [Abstract][Full Text] [Related]
8. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.
Alessandria C; Ottobrelli A; Debernardi-Venon W; Todros L; Cerenzia MT; Martini S; Balzola F; Morgando A; Rizzetto M; Marzano A
J Hepatol; 2007 Oct; 47(4):499-505. PubMed ID: 17560680
[TBL] [Abstract][Full Text] [Related]
9. Noradrenaline or terlipressin for hepatorenal syndrome?
Celis P; Rada G
Medwave; 2015 Aug; 15 Suppl 2():e6235. PubMed ID: 26334297
[TBL] [Abstract][Full Text] [Related]
10. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: A randomized controlled study.
Saif RU; Dar HA; Sofi SM; Andrabi MS; Javid G; Zargar SA
Indian J Gastroenterol; 2018 Sep; 37(5):424-429. PubMed ID: 30178092
[TBL] [Abstract][Full Text] [Related]
11. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial.
Solanki P; Chawla A; Garg R; Gupta R; Jain M; Sarin SK
J Gastroenterol Hepatol; 2003 Feb; 18(2):152-6. PubMed ID: 12542598
[TBL] [Abstract][Full Text] [Related]
13. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
Colle I; Durand F; Pessione F; Rassiat E; Bernuau J; Barrière E; Lebrec D; Valla DC; Moreau R
J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
[TBL] [Abstract][Full Text] [Related]
14. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
Wong F; Pappas SC; Boyer TD; Sanyal AJ; Bajaj JS; Escalante S; Jamil K;
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):266-272.e1. PubMed ID: 27464593
[TBL] [Abstract][Full Text] [Related]
15. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
Sagi SV; Mittal S; Kasturi KS; Sood GK
J Gastroenterol Hepatol; 2010 May; 25(5):880-5. PubMed ID: 20074149
[TBL] [Abstract][Full Text] [Related]
16. Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation.
Mattos ÂZ; Mattos AA; Ribeiro RA
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):345-51. PubMed ID: 26649801
[TBL] [Abstract][Full Text] [Related]
17. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
Neri S; Pulvirenti D; Malaguarnera M; Cosimo BM; Bertino G; Ignaccolo L; Siringo S; Castellino P
Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
[TBL] [Abstract][Full Text] [Related]
18. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome.
Uriz J; Ginès P; Cárdenas A; Sort P; Jiménez W; Salmerón JM; Bataller R; Mas A; Navasa M; Arroyo V; Rodés J
J Hepatol; 2000 Jul; 33(1):43-8. PubMed ID: 10905585
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.
Narahara Y; Kanazawa H; Sakamoto C; Maruyama H; Yokosuka O; Mochida S; Uemura M; Fukui H; Sumino Y; Matsuzaki Y; Masaki N; Kokubu S; Okita K
J Gastroenterol; 2012 Mar; 47(3):313-20. PubMed ID: 22038555
[TBL] [Abstract][Full Text] [Related]
20. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
Moreau R; Lebrec D
Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
